{"id":"https://openalex.org/W2258304092","doi":null,"title":"Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer","display_name":"Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer","alternate_titles":[],"publication_year":2007,"publication_date":"2007-11-01","ids":{"openalex":"https://openalex.org/W2258304092","mag":"2258304092"},"language":"en","primary_location":{"id":"mag:2258304092","doi":null,"is_oa":false,"landing_page_url":"https://mct.aacrjournals.org/content/6/11_Supplement/CN06-02","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2258304092"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059110616","display_name":"Mark Rolfe","orcid":"https://orcid.org/0009-0001-7585-2684","observed_orcids":["https://orcid.org/0009-0001-7585-2684"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Rolfe","raw_affiliation_strings":["Millennium Pharmaceuticals, inc. (Cambridge, MA)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, inc. (Cambridge, MA)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062887885","display_name":"Michael A. Milhollen","orcid":"https://orcid.org/0000-0003-1736-1219","observed_orcids":["https://orcid.org/0000-0003-1736-1219"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Milhollen","raw_affiliation_strings":["Millennium Pharmaceuticals, inc. (Cambridge, MA)"],"raw_orcid":"https://orcid.org/0000-0003-1736-1219","affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, inc. (Cambridge, MA)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010026747","display_name":"Allison Berger","orcid":"https://orcid.org/0000-0003-1217-2005","observed_orcids":["https://orcid.org/0000-0003-1217-2005"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison Berger","raw_affiliation_strings":["Millennium Pharmaceuticals, inc. (Cambridge, MA)"],"raw_orcid":"https://orcid.org/0000-0003-1217-2005","affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, inc. (Cambridge, MA)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067903367","display_name":"Pete Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pete Smith","raw_affiliation_strings":["Millennium Pharmaceuticals, inc. (Cambridge, MA)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, inc. (Cambridge, MA)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075750647","display_name":"Steven Langston","orcid":"https://orcid.org/0000-0001-5840-0005","observed_orcids":["https://orcid.org/0000-0001-5840-0005"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Langston","raw_affiliation_strings":["Millennium Pharmaceuticals, inc. (Cambridge, MA)"],"raw_orcid":"https://orcid.org/0000-0001-5840-0005","affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, inc. (Cambridge, MA)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063604217","display_name":"Teresa A. Soucy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teresa A. Soucy","raw_affiliation_strings":["Millennium Pharmaceuticals, inc. (Cambridge, MA)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, inc. (Cambridge, MA)","institution_ids":["https://openalex.org/I4405270001"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405270001"],"apc_list":null,"apc_paid":null,"fwci":0.0968,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.37320539,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"6","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mln4924","display_name":"MLN4924","score":0.9729999899864197},{"id":"https://openalex.org/keywords/nedd8-activating-enzyme-inhibitor","display_name":"NEDD8-activating enzyme inhibitor","score":0.9129999876022339},{"id":"https://openalex.org/keywords/ubiquitin-proteasome-system","display_name":"ubiquitin-proteasome system","score":0.9769999980926514},{"id":"https://openalex.org/keywords/dna-re-replication","display_name":"DNA re-replication","score":0.7390000224113464},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6759999990463257},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.5379999876022339},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.6710000038146973},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.5849999785423279},{"id":"https://openalex.org/keywords/small-molecule-inhibitors","display_name":"small molecule inhibitors","score":0.5789999961853027},{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.4359999895095825},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.6650000214576721},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.7609999775886536}],"concepts":[{"id":"https://openalex.org/C2779231659","wikidata":"https://www.wikidata.org/wiki/Q6953444","display_name":"NEDD8","level":5,"score":0.8551903963088989},{"id":"https://openalex.org/C45005369","wikidata":"https://www.wikidata.org/wiki/Q21115705","display_name":"Neddylation","level":5,"score":0.7642332315444946},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.6527525782585144},{"id":"https://openalex.org/C25602115","wikidata":"https://www.wikidata.org/wiki/Q407111","display_name":"Ubiquitin","level":3,"score":0.650964081287384},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5932261347770691},{"id":"https://openalex.org/C134459356","wikidata":"https://www.wikidata.org/wiki/Q4274835","display_name":"Ubiquitin ligase","level":4,"score":0.5378552675247192},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5318619608879089},{"id":"https://openalex.org/C2778567606","wikidata":"https://www.wikidata.org/wiki/Q41797435","display_name":"Cullin","level":5,"score":0.5183787941932678},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.5027813911437988},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.4931127727031708},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.4748280942440033},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.46131396293640137},{"id":"https://openalex.org/C2992195973","wikidata":"https://www.wikidata.org/wiki/Q33123","display_name":"Protein degradation","level":2,"score":0.4612523317337036},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.42992061376571655},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.393344521522522},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.33553197979927063},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3024260997772217},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.290229469537735},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.1721968650817871},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.08103525638580322},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07607421278953552},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2258304092","doi":null,"is_oa":false,"landing_page_url":"https://mct.aacrjournals.org/content/6/11_Supplement/CN06-02","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2076194625","https://openalex.org/W2106833644","https://openalex.org/W2007725104","https://openalex.org/W2069777002","https://openalex.org/W2551781691","https://openalex.org/W2101272346","https://openalex.org/W1985593766","https://openalex.org/W2549121500","https://openalex.org/W2783151804","https://openalex.org/W2147045066"],"abstract_inverted_index":{"CN06-02":[0],"1\u2028":[2],"Targeting":[3],"the":[4,7,20,25,83,87,122,139,145,167,178,204,241,263,267,276,288,291,346,361,367,374,380,383,411,428,480,484,493,523,529,547],"UPS":[5,140,184],"for":[6,17,79,198,379,539,595,617,664],"treatment":[8,123,146,433],"of":[9,19,45,113,124,138,147,166,180,183,210,220,235,243,246,262,269,278,283,290,297,323,341,373,382,389,397,405,410,414,440,455,470,483,519,531,544,620,639,644,666],"cancer\u2028":[10],"The":[11,173,525],"ubiquitin-proteasome":[12,88],"system":[13,90],"(UPS)":[14],"is":[15,28,54,196,377,615,662],"responsible":[16],"much":[18],"regulated":[21],"protein":[22,93],"turnover":[23],"in":[24,104,108,121,144,216,251,287,337,345,360,492,498,522,541,557,567,575],"cell":[26,35,38,109,130,249,264,270,292,476],"and":[27,40,49,66,95,128,207,253,348,366,442,457,565,578],"central":[29],"to":[30,190,223,274,329,438,475],"multiple":[31,125,468,581],"intracellular":[32],"processes":[33,99],"including":[34],"cycle":[36,293],"progression,":[37],"growth":[39,242,254,271,353,512,577],"differentiation,":[41],"signal":[42],"transduction,":[43],"regulation":[44],"transcription,":[46],"DNA":[47,285,305],"replication":[48],"repair":[50],"among":[51],"others.":[52],"Ubiquitination":[53],"a":[55,76,181,221,244,281,298,301,338,445,516,572],"multistep":[56],"process":[57],"involving":[58],"an":[59,153,163,394],"E1":[60],"ubiquitin-activating":[61],"enzyme,":[62],"E2":[63],"ubiquitin-conjugating":[64],"enzyme":[65,151,160,365],"E3":[67,185,193],"ligases,":[68],"which":[69,473,568],"select":[70],"targeted":[71],"substrates,":[72],"tagging":[73],"them":[74],"with":[75,86,213,257,304,434,500,515,537],"polyubiquitin":[77],"chain":[78],"subsequent":[80,208],"degradation":[81,89,209],"by":[82,295,622],"proteasome.":[84],"Interfering":[85],"will":[91,357],"disrupt":[92],"homeostasis":[94],"affect":[96],"numerous":[97],"cellular":[98],"that":[100,133,309,420,460,464,506,550],"are":[101],"commonly":[102],"deregulated":[103],"cancer":[105],"cells,":[106],"resulting":[107],"death.":[110],"As":[111,218],"proof":[112],"concept,":[114],"Millennium\u2019s":[115],"proteasome":[116],"inhibitor,":[117],"bortezomib,":[118],"has":[119,229],"utility":[120],"myeloma":[126],"(1)":[127],"mantle":[129],"lymphoma":[131,399,430,495],"suggesting":[132,463],"compounds":[134],"targeting":[135,619],"other":[136,452],"components":[137],"could":[141],"prove":[142,554],"useful":[143],"malignancies.\u2028":[148],"2\u2028":[149],"Nedd8-activating":[150,159,364],"as":[152,162,280,534,561],"anti-cancer":[154],"target\u2028":[155],"Millennium":[156,228],"scientists":[157],"identified":[158,230],"(NAE)":[161],"essential":[164,616],"component":[165],"Nedd8":[168,174,188,342,612,637],"conjugation":[169,175,189,613],"pathway":[170,176,343,369,376,407,614],"(2,":[171],"3).":[172],"controls":[177],"activity":[179,540,661],"subset":[182],"ligases.":[186],"Specifically,":[187],"cullin-dependent":[191],"ubiquitin":[192],"ligases":[194,202],"(CDLs)":[195],"necessary":[197],"their":[199],"activity.":[200,426],"These":[201,237,355],"control":[203],"timely":[205],"ubiquitination":[206,643],"many":[211,542],"proteins":[212],"important":[214],"roles":[215],"oncogenesis.\u2028":[217],"part":[219],"program":[222],"develop":[224],"new":[225],"oncology":[226],"drugs,":[227],"novel":[231],"small":[232],"molecule":[233],"inhibitors":[234,238,325,422,436,533,552],"NAE.":[236],"potently":[239],"inhibited":[240],"variety":[245],"human":[247,332],"tumor-derived":[248],"lines":[250,265,454],"vitro":[252],"inhibition":[255,272,344,472,513,521],"correlated":[256,514],"NAE":[258,318,324,421,435,471,520,532,551],"inhibition.":[259,354],"In":[260,320,427,487],"most":[261],"studied,":[266],"mechanism":[268],"appeared":[273],"be":[275,358,467],"induction":[277,296],"apoptosis":[279,316,443],"consequence":[282],"uncontrolled":[284],"synthesis":[286],"S-phase":[289],"followed":[294],"DNA-damage":[299],"response,":[300],"phenotype":[302],"consistent":[303],"re-replication.":[306],"Furthermore,":[307],"cells":[308],"were":[310,461,507],"not":[311,314],"cycling":[312],"did":[313],"undergo":[315],"upon":[317],"inhibition.\u2028":[319],"vivo":[321],"administration":[322],"at":[326,504],"well-tolerated":[327],"doses":[328,505],"mice":[330],"harboring":[331],"tumor":[333,347,352,453,485,501,511,576],"subcutaneous":[334],"xenografts":[335],"resulted":[336],"pharmacodynamic":[339,517],"response":[340,518],"translated":[349],"into":[350],"significant":[351,573],"data":[356,527,548],"discussed":[359],"presentation.\u2028":[362],"3\u2028":[363],"NF-\u03baB":[368,375,424,569],"Constitutive":[371,657],"activation":[372,404,570],"required":[378,663],"survival":[381,579,665],"activated":[384,667],"B-cell":[385,392],"like":[386],"(ABC)":[387],"subgroup":[388],"diffuse":[390],"large":[391],"lymphoma,":[393],"aggressive":[395],"form":[396],"non-Hodgkin\u2019s":[398],"(4).":[400],"Nedd8-dependent":[401],"CDL\u03b2TRCP":[402],"mediates":[403],"this":[406],"through":[408],"polyubiquitination":[409],"endogenous":[412],"inhibitor":[413],"NF-\u03baB,":[415],"I\u03baB\u03b1.":[416],"We":[417],"have":[418],"demonstrated":[419],"inhibit":[423],"transcriptional":[425],"NF-\u03baB-dependent":[429],"line,":[431],"OCI-Ly10,":[432],"led":[437],"accumulation":[439],"phospho-I\u03baB\u03b1":[441],"following":[444],"G1":[446],"arrest.":[447],"This":[448],"differed":[449],"from":[450],"all":[451],"epithelial":[456],"hematological":[458],"origin":[459],"characterized,":[462],"there":[465],"can":[466],"consequences":[469],"leads":[474],"death":[477],"depending":[478],"on":[479],"genetic":[481],"background":[482],"cells.\u2028":[486],"vivo,":[488],"efficacy":[489],"was":[490],"observed":[491,503],"OCI-Ly10":[494],"xenograft":[496],"model":[497],"mice,":[499],"regressions":[502],"well":[508],"tolerated.":[509],"Again,":[510],"tumors.\u2028":[524],"preclinical":[526],"support":[528],"development":[530],"anticancer":[535],"drugs":[536],"potential":[538],"types":[543],"cancer.":[545],"Moreover,":[546],"suggest":[549],"may":[553],"particularly":[555],"effective":[556],"\u201cNF-\u03baB-addicted\u201d":[558],"cancers":[559],"such":[560],"ABC":[562],"type":[563],"NHL":[564],"others":[566],"plays":[571],"role":[574],"(e.g.":[580],"myeloma).\u2028":[582],"References\u2028":[583],"1.\u2028":[584],"Richardson,":[585],"PG":[586],"et":[587,608,634,654],"al":[588,609,635,655],"(2005)":[589],"Bortezomib":[590],"or":[591],"High":[592],"Dose":[593],"Dexamethazone":[594],"Relapsed":[596],"Multiple":[597],"Myeloma.":[598],"N.":[599],"Engl.":[600],"J.":[601,676],"Med.":[602,678],"352;":[603],"2487-2498\u2028":[604],"2.\u2028":[605],"Podust,":[606],"VN":[607],"(2000)":[610,636],"A":[611],"proteolytic":[618],"p27KIP1":[621],"ubiquitination.":[623],"Proc.":[624],"Natl.":[625],"Acad.":[626],"Sci.":[627],"USA":[628],"97:":[629],"4579-4584\u2028":[630],"3.\u2028":[631],"Read,":[632],"MA":[633],"modification":[638],"Cul1":[640],"activates":[641],"SCF(beta(TrCP))-dependent":[642],"IkappaBalpha.":[645],"Mol.":[646],"Cell.":[647],"Biol.":[648],"20:":[649],"2326-2333\u2028":[650],"4.\u2028":[651],"Davis,":[652],"RE":[653],"(2001)":[656],"Nuclear":[658],"Factor":[659],"kB":[660],"B":[668,672],"cell-like":[669],"Diffuse":[670],"Large":[671],"Cell":[673],"Lymphoma":[674],"cells.":[675],"Exp.":[677],"194;":[679],"1861-1874":[680]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2258304092","counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}
